https://doi.org/10.4081/reumatismo.2013.79

Bosentan and sildenafil: successful treatment in a sclerodermic patient with refractory ulcers

Vol. 65 No. 2 (2013)
Submitted: 27 September 2012
Accepted: 9 May 2013
Published: 27 May 2013
Bosentan, Sildenafil, Ulcer, Sistemic sclerosis.
Abstract Views: 2916
PDF: 769
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

E. Catarsi
eleonoracatarsi@hotmail.com
U.O. Immunoallergologia, Ospedale S. Chiara, Pisa, Italy.
M. Doveri
U.O. Reumatologia, Ospedale S. Chiara, Pisa, Italy.
A. Tavoni
U.O. Immunoallergologia, Ospedale S. Chiara, Pisa, Italy.
Systemic sclerosis is an inflammatory disease of the connective tissue characterized by vasculopathy and accumulation of collagen and other components of the connective matrix, affecting the skin and internal organs. The appearance of skin ulcers as a result of vascular damage is very common in the history of the disease. Skin ulcers, painful and slow healing due to atrophy and local ischemia, get worse the quality of life of patients. Often, the use of conventional therapies (such as calcium channel blockers and prostanoids) does not cause the complete healing of the lesions. We report the case of a patient in whom therapeutic association between endothelin antagonist (bosentan) and phosphodiesterase-V inhibitor (sildenafil) resulted in complete healing of old ulcers both to upper and lower limbs and allowed the interruption of intravenous therapies.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

none

How to Cite

Catarsi, E., Doveri, M., & Tavoni, A. (2013). Bosentan and sildenafil: successful treatment in a sclerodermic patient with refractory ulcers. Reumatismo, 65(2), 79–81. https://doi.org/10.4081/reumatismo.2013.79

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.